A new report examines the safety of bivalent COVID boosters among 1.7 million over-50s

Brasil Notícia Notícia

A new report examines the safety of bivalent COVID boosters among 1.7 million over-50s
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 71%

A new report examines the safety of bivalent COVID boosters among 1.7 million over-50s Coronavirus Disease COVID bivalent boosters medrxivpreprint SSI_dk koebenhavns_uni

Bivalent messenger ribonucleic acid boosters targeting the ancestral SARS-CoV-2 and the Omicron BA.1 or BA.4/5 spikes were approved for use in 2022. These bivalent boosters were recommended following primary vaccination regardless of boosting with monovalent vaccines.

Study: Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study. Image Credit: Jo Panuwat D / Shutterstock The team evaluated the potential risk of 27 adverse events for SARS-CoV-2 vaccines. Outcome events were hospital visits, where outcome diagnoses were the main reasons to seek hospital care. Subjects were followed up from day 29 post-third/fourth dose until the first outcome, emigration, death, or study’s end.

Findings Overall, more than 2.2 million triple-vaccinated individuals were included in the cohort; their average age was 66.9 years, and most individuals were females. Among these, over 1.7 million subjects were boosted with the bivalent vaccine between September 15 and December 10, 2022.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

NewsMedical /  🏆 19. in UK

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2 MERS CoV SmallMolecule SARS SARSCoV2 Coronavirus Disease COVID biorxivpreprint SamuelMerrittU nybloodcenter
Consulte Mais informação »

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistanceSARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistanceIn a recent study posted to bioRxiv* preprint server, researchers at Ohio State University examined the degree of neutralizing antibody (nAb) evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5, CA.3.1, and CH.1.1 subvariants.
Consulte Mais informação »

Review on lateral flow test use spearheaded by SARS-CoV-2 pandemicReview on lateral flow test use spearheaded by SARS-CoV-2 pandemicResearchers assessed the changing landscape of lateral flow tests (LFTs), and the development of next-generation LFTs based on lessons learnt from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Consulte Mais informação »

Denmark Has a Controversial Reason for Scrapping a Public HolidayDenmark Has a Controversial Reason for Scrapping a Public HolidayDenmark’s Prime Minister Mette Frederiksen presented a bill to parliament that would abolish one of the country’s 11 public holidays, in order to pay for more military spending
Consulte Mais informação »

Researchers report a reduction in hospitalizations and deaths from SARS-CoV-2 infections during the Omicron variant-dominated wave in MalawiResearchers report a reduction in hospitalizations and deaths from SARS-CoV-2 infections during the Omicron variant-dominated wave in MalawiResearchers report a reduction in hospitalizations and deaths from SARS-CoV-2 infections during the Omicron variant-dominated wave in Malawi MlwTrust LivUni UofGlasgow LSHTM SARSCoV2 infection covid coronavirus covid Omicron
Consulte Mais informação »

Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccineResearchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccineResearchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine biorxivpreprint Stanford scrippsresearch UNC ULLafayette vaccine vaccinated SARSCoV2
Consulte Mais informação »



Render Time: 2025-03-07 01:36:25